|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 63.24 CHF | +1.18% |
|
-1.56% | -17.76% |
| Dec. 12 | Glass Lewis Reaffirms its Recommendations to Shareholders of STAAR | CI |
| Dec. 11 | Stocks Extend Losing Streak as Swiss National Bank Holds Key Rate at Zero | MT |
Business description: Alcon Inc.
- ophthalmic surgical products and equipment (56.1%): consumables (51.8% of net sales), implantable products (32.1%) and other products (16.1%; in particular surgical equipment) for the treatment of cataracts, retinal diseases, glaucoma and refractive errors;
- vision care products (43.9%): contact lenses (60.5% of sales) and eye care products (39.5%; eye drops and ophthalmic ointments, etc.).
At the end of 2024, the group operated 17 production sites worldwide.
Net sales are distributed geographically as follows: Switzerland (0.8%), the United States (45.9%), China (5.7%), Japan (5.6%) and other (42%).
Number of employees: 25,000
Sales by Activity: Alcon Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Surgical | 3.71B | 4.7B | 5.04B | 5.31B | 5.53B |
Vision Care | 3.12B | 3.59B | 3.67B | 4.14B | 4.38B |
Geographical breakdown of sales: Alcon Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
United States | 2.98B | 3.65B | 3.9B | 4.31B | 4.51B |
Rest of World | 2.7B | 3.4B | 3.66B | 3.88B | 4.13B |
China | 383M | 486M | 474M | 526M | 560M |
Japan | 650M | 621M | 568M | 583M | 554M |
Switzerland | 55M | 60M | 59M | 64M | 79M |
Executive Committee: Alcon Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
David Endicott
CEO | Chief Executive Officer | 59 | 2018-06-30 |
| Director of Finance/CFO | 57 | 2019-04-07 | |
Patrick Collier
CTO | Chief Tech/Sci/R&D Officer | - | 2024-12-31 |
Muru Murugappan
CTO | Chief Tech/Sci/R&D Officer | - | 2024-07-31 |
Ian Bell
COO | Chief Operating Officer | 55 | 2023-12-31 |
Composition of the Board of Directors: Alcon Inc.
| Director | Title | Age | Since |
|---|---|---|---|
David Endicott
BRD | Director/Board Member | 59 | - |
F. Ball
CHM | Chairman | 69 | 2018-06-30 |
Lynn Bleil
BRD | Director/Board Member | 62 | 2019-01-31 |
Arthur Cummings
BRD | Director/Board Member | 62 | 2018-12-31 |
| Director/Board Member | 66 | 2018-12-31 | |
D. Grossman
BRD | Director/Board Member | 64 | 2019-03-31 |
Scott Maw
BRD | Director/Board Member | 57 | 2018-12-31 |
Karen May
BRD | Director/Board Member | 66 | 2018-12-31 |
Ines Pöschel
BRD | Director/Board Member | 57 | 2018-12-31 |
Dieter Spälti
BRD | Director/Board Member | 64 | 2018-12-31 |
Holdings: Alcon Inc.
| Name | Equities | % | Valuation |
|---|---|---|---|
ALCON, INC. 1.02% | 5,083,676 | 1.02% | 403,186,344 $ |
OCUMENSION THERAPEUTICS 16.64% | 139,159,664 | 16.64% | 146,567,133 $ |
Company details: Alcon Inc.
Group companies: Alcon Inc.
| Name | Category and Sector |
|---|---|
Alcon Laboratories (India) Pvt Ltd.
 Alcon Laboratories (India) Pvt Ltd. Supplies eye care devices | |
Alcon Laboratories (India) Pvt Ltd.
Alcon Laboratories (India) Pvt Ltd. Supplies eye care devices | |
Alcon Finance BV
 Alcon Finance BV Functions as a financing subsidiary/special purpose entity | |
Alcon Management SA | |
Alcon Management SA |
Glasses, Spectacles & Contact Lenses
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.18% | -1.56% | -15.93% | -1.25% | 39.04B | |
| +0.14% | -6.83% | +22.19% | +61.47% | 153B | |
| -0.67% | +4.48% | -14.04% | +0.62% | 15.98B | |
| -0.17% | -1.02% | - | - | 7.75B | |
| -1.95% | -1.95% | +256.74% | +930.74% | 3.16B | |
| +0.20% | -3.98% | -21.52% | -55.37% | 1.9B | |
| -2.02% | -6.25% | -9.89% | -3.25% | 1.12B | |
| -1.75% | -1.20% | +5.51% | -45.60% | 762M | |
| -0.52% | -2.05% | -19.52% | -31.70% | 714M | |
| 0.00% | -4.08% | -31.88% | -48.99% | 381M | |
| Average | -0.55% | -1.62% | +19.07% | +89.63% | 22.4B | |
| Weighted average by Cap. | +0.20% | -4.74% | +15.22% | +56.13% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ALC Stock
- Company Alcon Inc.
Select your edition
All financial news and data tailored to specific country editions
